Biography
Jeremy Norris is a Co-Founder and CEO of Frontier Diagnostics, a clinical diagnostics company developing next-generation molecular assays for tissue pathology. Frontier Diagnostics proprietary diagnostic platform utilizes mass spectrometry to measure protein signature from tissue sections, while maintaining spatial registration with anatomical features. Dr. Norris has worked in both academic and industry with an emphasis in mass spectrometry and separation science. His work has resulted in the successful launch of numerous commercial products and services. Dr. Norris obtained a Ph.D. in Chemistry from Vanderbilt University where he is currently Associate Professor of Biochemistry & Chemistry and Managing Director of the Mass Spectrometry Research Center.
Clinical Dx Showcase:
Frontier Diagnostics, LLC
Frontier Diagnostics, LLC was founded to discover, develop, and commercialize innovative tissue-based diagnostics that improve patient care.
MelanoMap: Molecular Diagnosis Of Ambiguous Skin Lesions
MelanoMap is a protein based, molecular diagnostic developed on a novel Imaging Mass Spectrometry platform, a technology that combines the spatial information of microscopy with the unparalleled molecular specificity and sensitivity of mass spectrometry.
The PMWC 2020 Data Applications in Clinical Diagnostics Showcase will provide a 15-minute time slot for selected organizations, including commercial companies, clinical testing labs, and medical research institutions, to present their latest advancements, insights, applications, and technologies to an audience of clinicians, leading investigators, academic institutions, pharma and biotech, investors, and potential clients. We will learn about new technologies and findings that promise expedited, cost-effective, and accurate clinical diagnosis for early disease detection, treatment decisions, and disease prevention.